Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Montanide adjuvant (GM-CSF + Montanide)

Montanide + GM-CSF is a combination adjuvant system rather than a single biological target, primarily utilized to bolster the immunogenicity of therapeutic vaccines in oncology. Montanide, specifically the ISA 51 formulation, is a water-in-oil emulsion that functions by creating a depot effect at the injection site, which facilitates the slow and sustained release of antigens to the immune system (SEPPIC, 2023). Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) is a cytokine that acts as a potent immunostimulant by promoting the differentiation, maturation, and recruitment of dendritic cells and other professional antigen-presenting cells (StatPearls, 2023). Together, these components work synergistically to enhance the magnitude and duration of the immune response, particularly the activation of cytotoxic T-lymphocytes (National Cancer Institute, 2024). This combination is frequently used in clinical trials for peptide-based vaccines targeting tumor-associated antigens in diseases such as glioblastoma and melanoma (Journal of Clinical Oncology, 2019). By optimizing antigen presentation and providing necessary co-stimulatory signals, Montanide + GM-CSF helps overcome the immune tolerance often associated with advanced malignancies (Frontiers in Immunology, 2018).

Other names

GM-CSF/Montanide ISA 51Sargramostim and MontanideMontanide ISA-51 VG and GM-CSFGM-CSF and ISA-51Montanide ISA 720 and GM-CSF

Montanide creates a physical depot for slow antigen release while GM-CSF recruits and activates dendritic cells to enhance antigen presentation and T-cell activation.